SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6849)7/13/1999 1:41:00 AM
From: Rocketman  Read Replies (1) | Respond to of 9719
 
I'm the wrong person to answer that question George, but hopefully someone out there can.

Rman



To: aknahow who wrote (6849)7/14/1999 10:15:00 PM
From: hm  Read Replies (1) | Respond to of 9719
 
Not quite sure what you mean by "look back points" but I take a stab at the question anyway.

Unless one is performing an interim analysis (and taking the statistical power hit to do so), it is generally a regulatory no-no to unblind a trial prior to all the subjects completing all the pre-specified evaluations. This is especially true in pivotal efficacy trials.

Hope this helps.

Hank


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News